{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:07Z","timestamp":1789726327623,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"John E Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jsps.2022.02.010","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T07:17:55Z","timestamp":1645773475000},"page":"605-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether\/lumefantrine and atazanavir\/ritonavir-based antiretroviral regimen in patients living with HIV"],"prefix":"10.1007","volume":"30","author":[{"given":"Sikiru Olatunji","family":"Usman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Adekunle","family":"Oreagba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdulWasiu","family":"Busari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinwumi","family":"Akinyede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ololade","family":"Adewumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Rotimi","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayinka","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinka Adeyemi","family":"Fashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Oluwatoyin","family":"Agbaje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaimon Alani","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"22","key":"10.1016\/j.jsps.2022.02.010_b0005","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa1200501","article-title":"Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children","volume":"367","author":"Achan","year":"2012","journal-title":"N Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jsps.2022.02.010_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/fvl.10.89","article-title":"Atazanavir\/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults","volume":"6","author":"Achenbach","year":"2011","journal-title":"Future Virol."},{"issue":"2","key":"10.1016\/j.jsps.2022.02.010_b0015","first-page":"103","article-title":"Antiretrovirals and Co-prescribed drugs for people living with HIV\/AIDS (PLWHA) in a University Teaching Hospital SouthWest Nigeria","volume":"26","author":"Akanmu","year":"2015","journal-title":"West African J. Pharm."},{"issue":"1","key":"10.1016\/j.jsps.2022.02.010_b0020","first-page":"139","article-title":"Commonly prescribed drugs in HIV\/AIDS and patient\u2019s socio-demographic data: a case study of University of Ilorin teaching hospital (UITH), Ilorin Nigeria","volume":"7","author":"Anafi","year":"2008","journal-title":"Nigerian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jsps.2022.02.010_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-8-289","article-title":"Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base","volume":"8","author":"Bouchaud","year":"2009","journal-title":"Malar J."},{"key":"10.1016\/j.jsps.2022.02.010_b0030","unstructured":"Bristol\u2010Myers Squibb Company. BMS\u2010232632: atazanavir briefing document May 2003. Available from http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3950B1_01_Bristol MyersSquibb\u2010atazanavir.pdf. Accessed June 21, 2021."},{"issue":"3","key":"10.1016\/j.jsps.2022.02.010_b0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1476-5381.2012.02033.x","article-title":"Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms","volume":"167","author":"Burk","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jsps.2022.02.010_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/393976","article-title":"Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir\/Ritonavir in HIV-Infected Ugandan Adults","volume":"2011","author":"Byakika-Kibwika","year":"2011","journal-title":"Chemother. Res. Pract."},{"issue":"5","key":"10.1016\/j.jsps.2022.02.010_b0045","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/jac\/dkr596","article-title":"Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether-lumefantrine in HIV-infected Ugandan adults","volume":"67","author":"Byakika-Kibwika","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jsps.2022.02.010_b0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2125.2008.03332.x","article-title":"Relationship between HIV protease inhibitors and QTc-interval duration in HIV-infected patients: a cross-sectional study","volume":"67","author":"Charbit","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2022.02.010_b0055","unstructured":"Drugs.com. Artemether-lumefantrine Side Effects. https:\/\/www.drugs.com\/sfx\/ artemether-lumefantrine-side-effects.html. Accessed August 2021"},{"key":"10.1016\/j.jsps.2022.02.010_b0060","unstructured":"Drugs.com. Ritonavir side effects. https:\/\/www.drugs.com\/sfx\/ritonavir-side-effects.html. Accessed August, 2021"},{"key":"10.1016\/j.jsps.2022.02.010_b0070","doi-asserted-by":"crossref","unstructured":"Ericsson, T., Sundell, J., Torkelsson, A., 2014. Effects of artemisinin antimalarials on Cytochrome P450 enzymesin vitrousing recombinant enzymes and human liver microsomes: potential implications for combination therapies,Xenobiotica44 (7),615-626. https:\/\/doi: 10.3109\/00498254.2013.878815","DOI":"10.3109\/00498254.2013.878815"},{"issue":"3","key":"10.1016\/j.jsps.2022.02.010_b0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","article-title":"Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria","volume":"44","author":"Ezzet","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jsps.2022.02.010_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-37113-5","article-title":"Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method","volume":"9","author":"Funck-Brentano","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jsps.2022.02.010_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5395\/rde.2013.38.1.52","article-title":"Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis","volume":"38","author":"Kim","year":"2013","journal-title":"Restor. Dent. Endod."},{"issue":"2","key":"10.1016\/j.jsps.2022.02.010_b0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","article-title":"Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected Patients","volume":"42","author":"Jemsek","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jsps.2022.02.010_b0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/108729104323038874","article-title":"Review: Cross-Resistance Patterns Among HIV Protease Inhibitors","volume":"18","author":"Kozal","year":"2004","journal-title":"AIDS Patient Care and STDs"},{"issue":"4","key":"10.1016\/j.jsps.2022.02.010_b0100","first-page":"636","article-title":"The interaction between artemether-lumefantrine and lopinavir\/ritonavir-based antiretroviral regimen","volume":"79","author":"Kredo","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jsps.2022.02.010_b0105","first-page":"423","article-title":"Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes","volume":"277","author":"Kumar","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jsps.2022.02.010_b0110","doi-asserted-by":"crossref","unstructured":"Kwenti, T.E., 2018. Malaria and HIV co-infection in sub-Saharan Africa: Prevalence, Impact and Treatment Strategies. Res. Rep. Trop. Med. 9, 123\u2013136. https:\/\/doi:10.2147\/RRTM.S154501","DOI":"10.2147\/RRTM.S154501"},{"key":"10.1016\/j.jsps.2022.02.010_b0115","doi-asserted-by":"crossref","unstructured":"Lef\u00e8vre, G., Thomsen, M.S., 1999. Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet\u00ae). Clin. Drug Investig. 18, 467\u2013480.","DOI":"10.2165\/00044011-199918060-00006"},{"key":"10.1016\/j.jsps.2022.02.010_b0120","doi-asserted-by":"crossref","unstructured":"Lopes, R.H.C., 2011. Kolmogorov-Smirnov Test. In: Lovric M, ed. International Encyclopedia of Statistical Science. Berlin Heidelberg: Springer, 2011. https:\/\/doi.org\/10.1007\/978-3-642-04898-2_326.","DOI":"10.1007\/978-3-642-04898-2_326"},{"issue":"4","key":"10.1016\/j.jsps.2022.02.010_b0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jmii.2010.08.003","article-title":"Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia","volume":"44","author":"Lu","year":"2011","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"6","key":"10.1016\/j.jsps.2022.02.010_b0130","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1086\/511875","article-title":"Prolonged QT Interval and Torsades de Pointes Associated with Atazanavir Therapy","volume":"44","author":"Ly","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"23","key":"10.1016\/j.jsps.2022.02.010_b0135","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1056\/NEJM199512073332204","article-title":"A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection","volume":"333","author":"Markowitz","year":"1995","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.02.010_b0140","doi-asserted-by":"crossref","unstructured":"Moyle, G.J., Back, D., 2001. Principles and Practice of HIV protease inhibitor pharmaco-enhancement. HIV MED. 2, 105-113. https:\/\/doi: 10.1046\/j.1468-1293.2001.00063.x","DOI":"10.1046\/j.1468-1293.2001.00063.x"},{"key":"10.1016\/j.jsps.2022.02.010_b0145","doi-asserted-by":"crossref","unstructured":"Murphy, R.l., Berzins, B., Zala, C., 2010. Change to atazanavir\/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 24 (6), 885\u2013890. https:\/\/doi: 10.1097\/QAD.0b013e3283352ed5.","DOI":"10.1097\/QAD.0b013e3283352ed5"},{"key":"10.1016\/j.jsps.2022.02.010_b0155","doi-asserted-by":"crossref","unstructured":"Noor, M.A., Flint, O.P., Maa, J.F., 2006. Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20 (14), 1813-1821. https:\/\/doi: 10.1097\/01.aids.0000244200.11006.55.","DOI":"10.1097\/01.aids.0000244200.11006.55"},{"issue":"1","key":"10.1016\/j.jsps.2022.02.010_b0160","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.22374\/1710-6222.26.1.1","article-title":"Clinically significant drug-drug interaction in a large antiretroviral treatment Centre in Lagos","volume":"26","author":"Oreagba","year":"2019","journal-title":"Nigeria. J. Popul. Ther. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2022.02.010_b0165","first-page":"205","article-title":"Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele","volume":"10","author":"Panagopoulos","year":"2017","journal-title":"Pharmgenomics Pers. Med."},{"issue":"6","key":"10.1016\/j.jsps.2022.02.010_b0170","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/dmd.104.002931","article-title":"Atazanavir: Effects on p-glycoprotein transport and CYP3A metabolism in-vitro","volume":"33","author":"Perloff","year":"2005","journal-title":"Drug Metab and Dispos."},{"issue":"10","key":"10.1016\/j.jsps.2022.02.010_b0175","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/503566","article-title":"HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy--Induced Nephropathy","volume":"42","author":"Roling","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"3\u20134","key":"10.1016\/j.jsps.2022.02.010_b0185","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","article-title":"An analysis of variance test for normality (complete samples)","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.jsps.2022.02.010_b0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jphs.2020.07.013","article-title":"Effect of nevirapine, efavirenz and lopinavir\/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital","volume":"144","author":"Usman","year":"2020","journal-title":"Nigeria. J. Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.jsps.2022.02.010_b0195","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-021-03116-x","article-title":"Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital","volume":"77","author":"Usman","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jsps.2022.02.010_b0200","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4269\/ajtmh.1999.61.964","article-title":"No evidence of cardiotoxicity during antimalarial treatment with Artemether-lumefantrine","volume":"61","author":"Ezzet","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.jsps.2022.02.010_b0205","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/17425255.3.4.583","article-title":"The Role of Cytochrome P450 in Antiretroviral Drug Interactions","volume":"3","author":"Walubo","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jsps.2022.02.010_b0210","doi-asserted-by":"crossref","unstructured":"Whitworth, J., Quigley, M.L., 2000. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda. Lancet Infect Dis. 356, 1051\u20131056. https:\/\/doi: 10.1016\/S0140-6736(00)02727-6","DOI":"10.1016\/S0140-6736(00)02727-6"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:27:55Z","timestamp":1736184475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016422000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1319016422000512"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2022.02.010","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether\/lumefantrine and atazanavir\/ritonavir-based antiretroviral regimen in patients living with HIV","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2022.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}